Anti-Cancer Drug 2.0% BHT/No BHT Everolimus Powder CAS 159351-69-6

Product Details
Customization: Available
Powder: Yes
Customized: Customized
Diamond Member Since 2019

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

to see all verified strength labels (11)
  • Anti-Cancer Drug 2.0% BHT/No BHT Everolimus Powder CAS 159351-69-6
  • Anti-Cancer Drug 2.0% BHT/No BHT Everolimus Powder CAS 159351-69-6
  • Anti-Cancer Drug 2.0% BHT/No BHT Everolimus Powder CAS 159351-69-6
  • Anti-Cancer Drug 2.0% BHT/No BHT Everolimus Powder CAS 159351-69-6
Find Similar Products

Basic Info.

Model NO.
top quality
Certification
GMP, HSE, ISO 9001, USP, BP
Suitable for
Elderly, Adult
State
Solid
Purity
>99%
CAS No.
N/a
Einecs No.
N/a
Mf
N/a
MW
N/a
Appearance
White Powder
MOQ
1g
Storge
2-8 Degree
Exp.
24 Months
Transport Package
Per Tin
Specification
1g/bag
Trademark
senwayer
Origin
China
HS Code
2601111000
Production Capacity
10kg Per Month

Product Description

Anti-cancer drug 2.0% BHT/No BHT Everolimus powder CAS 159351-69-6
Anti-Cancer Drug 2.0% BHT/No BHT Everolimus Powder CAS 159351-69-6

 

Physical Characters and specifications

Product name Everolimus 2.0% BHT or No BHT
CAS No. 159351-69-6
Molecular Formula C53H83NO14
Molecular weight 958.232
EINECS NO. 621-003-9
Grade Standard Medicine Grade
COA Avaliable
 
Item Specifications
Appearance Off-white powder.
Purity 99%min
Boiling point
998.7±75.0ºC at 760 mmHg
Density 1.2±0.1 g/cm3
Refractive index 1.548
Flash point 2ºC
PSA 204.66000
LogP 3.35
Solubility H2O:Soluble in dimethysulfoxide,ethanol. Slightly soluble in water.
Stability Hygroscopic
Storage condition -20ºC
Shelf life 3 years



Product Introduction
Everolimus (RAD001) is an orally active derivative of rapamycin that inhibits Ser / Thr kinase mTOR [1]. In sensitive mouse B16/BL6 melanoma (IC50, 0.7 nM) and insensitive human cervical KB-31 (IC50, 1,778 nM), the antiproliferative concentration of everolimus resulted in a total of S6K1 and substrate S6. Dephosphorylation and changes in mobility. 4E-BP1, indicating a decrease in phosphorylation status [2]. Everolimus showed dose-dependent inhibition in total cells and stem cells from the BT474 cell line and primary breast cancer cells, albeit with varying degrees of growth inhibition. Compared with total cells, everolimus had a poor inhibitory effect on stem cell growth at all concentrations tested (P < 0.001). The IC50 values of everolimus against BT474 and primary CSC were 2,054 and 3,227 nM, respectively, or 29 and 21 times the IC50 values of their respective total cells, respectively.

Target
Serine/threonine-protein kinase mTOR

Enzyme
Cytochrome P450 3A4
 

Function
Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination, after failure of treatment . Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease. Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.


Associated Conditions:
Heart Transplant Rejection;
Kidney Transplant Rejection;
Liver Transplant Rejection;
Renal angiomyolipoma, tuberous sclerosis complex;
Subependymal giant cell astrocytoma, tuberous sclerosis complex;
Advanced Carcinoid tumor;
Locally advanced gastrointestinal origin Progressive Neuroendocrine Tumors;
Locally advanced lung origin Progressive Neuroendocrine Tumors;
Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors;
Metastatic lung origin Progressive Neuroendocrine Tumors;
Pancreatic origin Progressive Neuroendocrine Tumors;
Refractory Advanced Renal Cell Carcinoma;
Refractory Waldenstrom's Macroglobulinaemia;
Refractory, advanced Breast cancer;
Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors;
Unresectable lung origin Progressive Neuroendocrine Tumors

Anti-Cancer Drug 2.0% BHT/No BHT Everolimus Powder CAS 159351-69-6

Anti-Cancer Drug 2.0% BHT/No BHT Everolimus Powder CAS 159351-69-6
Anti-Cancer Drug 2.0% BHT/No BHT Everolimus Powder CAS 159351-69-6Anti-Cancer Drug 2.0% BHT/No BHT Everolimus Powder CAS 159351-69-6

Anti-Cancer Drug 2.0% BHT/No BHT Everolimus Powder CAS 159351-69-6

Anti-Cancer Drug 2.0% BHT/No BHT Everolimus Powder CAS 159351-69-6

Anti-Cancer Drug 2.0% BHT/No BHT Everolimus Powder CAS 159351-69-6
Anti-Cancer Drug 2.0% BHT/No BHT Everolimus Powder CAS 159351-69-6
Anti-Cancer Drug 2.0% BHT/No BHT Everolimus Powder CAS 159351-69-6
Anti-Cancer Drug 2.0% BHT/No BHT Everolimus Powder CAS 159351-69-6
Anti-Cancer Drug 2.0% BHT/No BHT Everolimus Powder CAS 159351-69-6

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier